Naslov
Higher Sclerostin/SOST expression is associated with lower percentage of circulatory blasts and better prognosis in patients with myelofibrosis

Autori
Lucijanic M, Livun A, Tupek KM, Stoos-Veic T, Pejsa V, Kusec R.

Izvornik
Annals of hematology (0939-5555) 97 (2018), 7; 1293-1294

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo, stručni

Ključne riječi
philadelphia negative myeloproliferation ; myelofibrosis, SOST expression, sclerostin

Sažetak
Sclerostin (a product of SOST gene) acts as a main negative regulator of bone metabolism, exerting its properties through inhibition of canonical-WNT signaling-pathway (cWNT) in osteoblasts [1]. It is produced by osteocytes and bone marrow (BM) cells. cWNT activation is implicated in pathogenesis of Philadelphia chromosome-negative myeloproliferative neoplasms (Ph- MPNs) [2, 3], diseases characterized by remodeling of BM stroma and development of BM fibrosis/ osteosclerosis during course of the disease. We aimed to investigate Sclerostin/SOSTexpression in BMtissues of patients with primary (PMF) and secondary post Ph- MPN myelofibrosis (SMF) and to assess its clinical correlations. We retrospectively investigated Sclerostin/SOST expression in BM of 66 diseased patients (51 PMF, 15 post-PV/ post-ET-SMF,

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA